April 2021 in “Research Square (Research Square)” The new cocrystal KET-PABA is a more effective and safe anti-inflammatory treatment for skin conditions in mice.
69 citations
,
December 2005 in “Nature Clinical Practice Endocrinology & Metabolism” Blocking the enzyme 11β-HSD1 might help treat obesity and metabolic issues.
January 2021 in “Journal of Cancer Therapy” Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.
20 citations
,
August 2020 in “Stem Cell Research & Therapy” miR-150 helps blood vessel cells develop and speeds up blood clot healing.
6 citations
,
March 2022 in “Frontiers in drug discovery” Some small molecule antivirals show promise against COVID-19, but more research is needed to understand and improve them.
January 2005 in “世界胃肠病学杂志:英文版(电子版)” Etoposide makes radiation therapy more effective against tumors without major side effects.
508 citations
,
June 2009 in “Current drug metabolism” Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.
February 2025 in “International Journal of Morphology” Vitamin E can reduce the negative effects of valproic acid on hair and skin development.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Topical Vorinostat shows promise for treating alopecia areata by promoting hair regrowth.
2 citations
,
February 2025 in “Advanced Healthcare Materials” Perhexiline can effectively target ovarian cancer cells left after treatment.
24 citations
,
July 2021 in “Pharmaceutics” Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
35 citations
,
May 2008 in “Journal of Clinical Oncology” A cancer patient died from a severe skin reaction after taking the drug cetuximab.
20 citations
,
May 2011 in “Journal of Clinical Investigation” The study created a mouse model to mimic degenerative diseases for testing tissue repair and new therapies.
March 2007 in “Journal of Cell Science” K10 may not prevent tumors as previously thought and might increase benign tumor risk.
8 citations
,
January 2013 in “Medicinal chemistry” The compound 4c showed strong potential as an anticancer agent.
6 citations
,
August 2014 in “Toxicologic pathology” Blocking DGAT1 reduces oil gland size in mice and dogs, but only mice experience hair loss.
Convulsofin effectively treats primary epilepsy but has some side effects.
9 citations
,
June 2014 in “Nutrition and Cancer” Eclipta alba extract may work as an anticancer agent and help reverse drug resistance.
January 2023 in “Cutaneous and Ocular Toxicology”
25 citations
,
March 2019 in “Dermatologic therapy” Intralesional therapy for keratoacanthoma is effective and has fewer side effects than systemic treatments.
January 1978 in “Clin-Alert” A document listed serious side effects from various drugs, including deaths and diseases, emphasizing the importance of being aware of drug side effects.
April 2010 in “Cancer Research” Basal cell carcinomas may use IDO to protect themselves from the immune system.
May 2025 in “Journal of Inflammation Research” A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.
6 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism” MK-386 and finasteride together effectively reduce DHT levels, potentially treating acne and male pattern baldness.
18 citations
,
December 2016 in “European journal of pharmacology” A new compound slows cancer cell growth and causes cell death by blocking cell cycle progression and increasing cell-damaging molecules.
1 citations
,
July 2020 in “Acta Neuropsychologica” Valproic acid effectively reduces aggressive and impulsive behaviors in brain injury patients with acceptable side effects.
12 citations
,
December 2021 in “Frontiers in Medicine” Some patients on immunosuppressants had a weaker immune response to the Sinovac-CoronaVac COVID-19 vaccine.
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
1 citations
,
May 1992 in “Pharmacological Research”
13 citations
,
July 2019 in “Toxicology research” Ethanamizuril is safe for rats at 20 mg/kg feed, but higher doses cause hair loss, organ changes, and liver, kidney, and lung damage.